Mylan's Herceptin biosimilar gets FDA approval

FDA approved Ogivri trastuzumab-dkst (MYL-1401O, CANMab, Hertraz) from Mylan N.V. (NASDAQ:MYL; Tel Aviv:MYL), a biosimilar of cancer drug

Read the full 182 word article

User Sign In